Innovent doses first patient in Phase I trial of IBI315 in China

CIBI315A101 is a Phase I clinical trial conducted in China to evaluate the safety, tolerability, initial efficacy and recommended Phase II dose of IBI315. Credit: Pixabay.



  • Innovent